• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
BYL719

BYL719

Product ID B9700
Cas No. 1217486-61-7
Purity ≥99%, ≥99%ee
Product Unit SizeCostQuantityStock
1 mg $63.00 In stock
5 mg $116.00 In stock
25 mg $173.00 In stock
100 mg $446.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

BYL-719 is an ATP-competitive oral PI3K inhibitor selective for the p110α isoform that is activated by a mutant PIK3CA gene in HER2+ breast cancers and gastric cancers. BYL-719 exhibits anticancer chemotherapeutic activity and inhibits proliferation in a variety of cell lines. IGF1 and neuregulin 1 activate mTOR, a downstream target of PI3K that mediates resistance to BYL-719 in some in vitro cancer models. This compound also decreases invasion and epithelial-to-mesenchymal transition (EMT) in cellular and animal models of squamous cell lung cancer.

Product Info

Cas No.

1217486-61-7

Purity

≥99%, ≥99%ee

Formula

C19H22F3N5O2S

Formula Wt.

441.47

Chemical Name

(2S)-1-N-[4-methyl-5-[2-(1,1, 1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1, 3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide

IUPAC Name

(2S)-1-N-[4-methyl-5-[2-(1,1, 1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1, 3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide

Synonym

Alpelisib, NVP-BYL719, BYL-719

Solubility

DMSO 88 mg/mL (199.33 mM) Ethanol 2 mg/mL (4.53 mM) Water Insoluble

Appearance

White Crystal Powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

B9700 MSDS PDF

Info Sheet

B9700 Info Sheet PDF

References

Bonelli MA, Cavazzoni A, Saccani F, et al. Inhibition of PI3K pathway reduces invasiveness and epithelial-to-mesenchymal transition in squamous lung cancer cell lines harboring PIK3CA gene alterations. Mol Cancer Ther. 2015 May 26. [Epub ahead of print]. PMID: 26013318.

Elkabets M, Vora S, Juric D, et al. mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer. Sci Transl Med. 2013 Jul 31;5(196):196ra99. PMID: 23903756.

Abstract: Juric. BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. American Association for Cancer Research. 2012.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • M1575

    7-Methyl-6-mercaptopurine

    Thiopurine antimetabolite; PRPP amidotransferas...

    ≥87%
  • P6800

    Pravastatin Lactone

    Statin; HMG-CoA reductase inhibitor.

    ≥98%
  • B0025

    Bafilomycin A1

    Macrolide antibiotic; vacuolar H+ ATPase inhibi...

    ≥90%
  • C2943

    Chlorogenic Acid (from Eucommia)

    Polyphenol derivative of caffeic acid found in ...

    ≥98%
  • C0262

    L-Carnitine

    Endogenous quaternary ammonium, required for fa...

    ≥98%
  • Y0052

    Yangonin

    Dienolide kavalactone originally found in Piper...

    ≥98%
  • P9668

    Pyrantel Pamoate

    Mixture of pyrantel, a thiophene, and pamoic ac...

    ≥98%
  • S0245

    Salmeterol

    β2-adrenergic agonist.

    ≥98%
  • T7156

    Tropisetron Hydrochloride

    α7 nAChR partial agonist, 5-HT3 antagonist.

    ≥98%
  • A5032

    D,L-Aminoglutethimide

    Aromatase inhibitor.

    ≥98%
  • P2810

    Phenylbutazone

    NSAID; COX-1/2 inhibitor.

    ≥98%
  • C2942

    Mechlorethamine Hydrochloride

    Nitrogen mustard, DNA alkylator.

    ≥98%
  • S5753

    Somatostatin-28 (1-14)

    Endogenous neuropeptide hormone; somatostatin a...

    ≥95%
  • G4400

    Glabridin

    Isoflavonoid found in Glycyrrhiza; GABA-A posit...

    ≥98%
  • G0243

    (−)-Gallocatechin

    Polyphenol found in Camilla sinensis; HIV integ...

    ≥98%
  • D178589

    1-Deoxynojirimycin

    Anti-diabetic alkaloid

    ≥98%
  • D5747

    Dolasetron Mesylate Hydrate

    5-HT3 antagonist.

    ≥98%
  • R520002

    RN-1747

    TRPV4 agonist

    ≥98%
  • A7657

    Atosiban Acetate

    Peptide, alters uterine contractility; V1/2 and...

    ≥95%
  • U482046

    (-)-Umbellulone

    Antimicrobial found in essential oils from plan...

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2026 LKT Laboratories, All Rights Reserved - Products for research use only